Citations refer to the original publication, not to a Scieee localized version.
Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Cruz Merino, L. D. L., & Fasching, P. A. (2021). Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Elsevier. https://doi.org/10.1016/j.annonc.2021.05.353
Slamon, D. J., et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Elsevier, 2021. https://doi.org/10.1016/j.annonc.2021.05.353.
Slamon, D. J., P. Neven, S. Chia, G. Jerusalem, M. De Laurentiis, S. Im, Luis de la Cruz Merino, and P. A. Fasching. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Elsevier, 2021. https://doi.org/10.1016/j.annonc.2021.05.353.
Slamon, D. J. et al. (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Elsevier. Available at: https://doi.org/10.1016/j.annonc.2021.05.353.
D. J. Slamon et al., “Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival,” Elsevier, 2021, doi: 10.1016/j.annonc.2021.05.353.
@misc{slamon2021ribociclib,
author = {Slamon, D. J. and Neven, P. and Chia, S. and Jerusalem, G. and De Laurentiis, M. and Im, S. and Cruz Merino, Luis de la and Fasching, P. A.},
title = {Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival},
year = {2021},
publisher = {Elsevier},
doi = {10.1016/j.annonc.2021.05.353},
url = {https://doi.org/10.1016/j.annonc.2021.05.353}
}
The source metadata has no journal, volume or pages. Add them from the original publication if your citation needs them.
